A Study of LY4060874 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-02

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 18 study visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of LY3074828 in Healthy Participants

NCT03748940

Healthy

COMPLETED PHASE1

A Study of LY4088044 in Healthy Participants

NCT07090785

Healthy

RECRUITING PHASE1

A Study of LY3079514 in Healthy Participants

NCT02242903

Healthy Volunteers

COMPLETED PHASE1

A Study of Galcanezumab in Healthy Participants

NCT02576951

Healthy

COMPLETED PHASE1

A Study of LY3016859 in Healthy Volunteers

NCT01545583

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY4060874 (Part A Subcutaneous)

Single ascending dose of LY4060874 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY4060874

Intervention Type DRUG

Administered SC

LY4060874 (Part A Intravenous)

Single ascending dose of LY4060874 administered intravenously (IV).

Group Type EXPERIMENTAL

LY4060874

Intervention Type DRUG

Administered IV

LY4060874 (Part B)

Multiple ascending doses of LY4060874 administered SC.

Group Type EXPERIMENTAL

LY4060874

Intervention Type DRUG

Administered SC

LY4060874 (Part B Chinese)

Multiple ascending doses of LY4060874 administered SC in Chinese participants.

Group Type EXPERIMENTAL

LY4060874

Intervention Type DRUG

Administered SC

LY4060874 (Part C Japanese)

Multiple ascending doses of LY4060874 administered SC in Japanese participants.

Group Type EXPERIMENTAL

LY4060874

Intervention Type DRUG

Administered SC

Placebo (SC)

Placebo administered SC in Part A, B, and C.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Placebo (IV)

Placebo administered IV in Part A.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY4060874

Administered SC

Intervention Type DRUG

LY4060874

Administered IV

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Placebo

Administered IV

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
* Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
* To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
* To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion Criteria

* Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
* Have hemoglobin A1c (HbA1c) \> 6.4% or 46 millimoles/mole (mmol/mol) at screening.
* Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
* Have had surgical treatment for obesity.
* Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes